Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
On May 30, 2024, Oncocyte announced that favorable results for its VitaGraft Kidney test were published in the New England Journal of Medicine. Data from a phase 2 study indicated that the test could monitor graft injury and identify responses to the investigational drug felzartamab. Results showed significant reductions in donor-derived cell-free DNA (dd-cfDNA) levels at weeks 12 and 24. This advancement suggests potential new uses for VitaGraft Kidney in monitoring therapeutic efficacy and recurrence of antibody-mediated rejection (AMR) in kidney transplant patients. Up to 20.2% of kidney transplant patients develop AMR within 10 years, often leading to graft failure. Oncocyte’s CEO, Josh Riggs, emphasized the potential for VitaGraft to improve care and outcomes for high-risk patients.
- Publication of favorable VitaGraft Kidney study results in the New England Journal of Medicine.
- VitaGraft Kidney showed significant reductions in dd-cfDNA levels at weeks 12 and 24.
- Potential new uses for VitaGraft Kidney in monitoring therapeutic efficacy and recurrence of AMR.
- VitaGraft can detect responsiveness to felzartamab therapy and uncover disease recurrence.
- Up to 70% of patients with AMR progress to graft failure; VitaGraft could address this unmet need.
- Partnership with Bio-Rad to support global transplant research community.
- Potential for multiple tests during active management phase and long-term monitoring.
- Presentation of results as a Late Breaking Abstract at the 2024 American Transplant Congress.
- No current FDA-approved drugs for management of AMR.
- High percentage (up to 70%) of kidney transplant patients with AMR progress to graft failure.
- Uncertainty in regulatory approval and market adoption of the new test applications.
Insights
The publication of favorable study results for Oncocyte's VitaGraft Kidney in the New England Journal of Medicine marks a noteworthy development. One of the most significant insights from this trial is the ability of VitaGraft to detect responsiveness to felzartamab therapy by monitoring donor-derived cell-free DNA (dd-cfDNA). This is important as it potentially allows for more personalized dosing intervals and durations of anti-rejection therapy, addressing a critical need in transplant management.
Monitoring dd-cfDNA offers the advantage of identifying graft health and disease recurrence efficiently, which can be transformative for patients who have undergone kidney transplants. Given that antibody-mediated rejection (AMR) leads to a significant number of transplant failures, an early and accurate diagnostic tool can enhance patient outcomes substantially. Furthermore, the potential for repeat testing during the active management phase and long-term monitoring adds significant value to this diagnostic approach.
This development has far-reaching implications for the field, especially considering the lack of FDA-approved drugs specifically for managing AMR. While the technology is promising, the transition from phase 2 trials to broader clinical practice will require further validation in larger cohorts and potentially FDA approval for these new indications.
Rating: 1
Oncocyte's recent announcement holds considerable financial implications for the company. The positive results published in the New England Journal of Medicine can bolster investor confidence and potentially drive stock value up in the short term. By demonstrating the effectiveness of VitaGraft Kidney in monitoring and managing AMR, Oncocyte can open new revenue streams through repeat testing during the active management phase and long-term follow-ups. This represents a substantial market given the high rates of kidney transplant failures due to AMR.
Moreover, the company's partnership with Bio-Rad provides Oncocyte with the scale needed to support global adoption of their dd-cfDNA monitoring tools, which could further enhance their market presence and profitability. However, investors should note that while the study results are promising, the path to regulatory approval and widespread clinical adoption involves significant time and resources.
In the long term, if the technology gains FDA approval and sees broad clinical use, it could become a cornerstone of Oncocyte's revenue model, contributing to sustained growth. However, it is important to monitor subsequent studies and regulatory milestones closely to assess the actual commercial potential.
Rating: 1
The introduction of VitaGraft Kidney as a diagnostic tool for monitoring graft health in kidney transplant patients represents a significant market opportunity. The ability to measure dd-cfDNA fractions provides not only a means to assess the efficacy of felzartamab therapy but also to detect early signs of AMR recurrence. This positions Oncocyte at the forefront of precision diagnostics in transplant care.
With an estimated 20.2% of kidney transplant patients developing AMR within a decade, the market for effective diagnostic tests is substantial. Most importantly, the study points out potential uses beyond the initial indications, suggesting a dual role in both therapeutic efficacy monitoring and long-term disease management. This diversification in application can drive higher adoption rates among healthcare providers.
Oncocyte's strategic partnership with Bio-Rad to leverage their distribution network further underscores the commercial potential of VitaGraft. By enabling easier access to dd-cfDNA testing tools, Oncocyte can reach a broader market and enhance their competitive position. However, market penetration will depend heavily on further clinical validations and subsequent regulatory approvals.
Rating: 1
- Late-breaking presentation of data at American Transplant Congress on Monday, June 3
- Data show potential to monitor for therapeutic efficacy and recurrence
- Potential repeat testing opportunities with claims expansion
IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine. Oncocyte’s Drs. Ekke Schuetz and Julia Beck, inventors of the technology, are among the authors of the study. VitaGraft Kidney was used to monitor graft injury in a phase 2 double-blind, placebo-controlled study (NCT05021484) of the investigational drug felzartamab, a fully human CD38 monoclonal antibody, for antibody-mediated rejection (AMR), a leading cause of kidney allograft failure.
VitaGraft Kidney measures the amount of DNA in transplant patients’ blood that comes from the donor organ, a key biomarker for assessing graft health. This process is commonly referred to as donor-derived cell-free DNA (dd-cfDNA) testing and is widely used in clinical practice today. In this study, Oncocyte’s proprietary diagnostic test using droplet-digital PCR was able to identify responders and non-responders to felzartamab, showing, “a decrease in dd-cfDNA fractions at week 12 (
The study points to new clinical utilities for VitaGraft Kidney beyond the Company’s currently approved and reimbursed indication of for cause testing. Both therapeutic efficacy and recurrence monitoring are potential new use cases for dd-cfDNA testing. Both utilities would be expected to require multiple tests during the active management phase, when a drug is being given, and long-term to help doctors watch for AMR recurrence.
“The results of the phase 2 trial suggested that monitoring of dd-cfDNA could be useful to accurately detect responsiveness to felzartamab therapy, also uncovering disease recurrence after stopping treatment,” said Dr. Georg Böemig, Medical University of Vienna, senior author of the publication. “Therefore, the assay could have high potential as a tool to individually guide dosing intervals and duration of anti-rejection therapy.”
Up to
“We congratulate the research teams on this groundbreaking study and its potential to lead to a treatment option for kidney transplant patients suffering from AMR around the world,” said Josh Riggs, Oncocyte CEO. “We are grateful for the support from our research partners and their inclusion of our test in this study. It is exciting to see a new opportunity for Oncocyte’s technology to serve the clinical market and patients in need. This study, combined with earlier results showing that our test can detect AMR up to 10 months earlier than protocol, points to new opportunities to improve care and outcomes for these high-risk patients. In the future, we expect that VitaGraft will be there to support physicians looking to detect AMR as early as possible and then effectively manage this disease.”
“Our recent partnership with Bio-Rad, gives us the scale we need to support the global transplant research community with easy-to-use dd-cfDNA monitoring tools,” continued Mr. Riggs. “Use cases like this will help drive adoption of our combined technology around the world.”
The results of this publication will be discussed as a Late Breaking Abstract at the 2024 American Transplant Congress on June 3rd 2024 at 9:15 ET by Dr. Katharina Mayer from the Medical University of Vienna. Oncocyte will be exhibiting at the conference at Booth #430.
Oncocyte will be hosting a conference call to discuss the results of the clinical trial with study authors, Dr. Klemens Budde, Head of Transplantation at Charite, and Dr. Ekke Schuetz, Chief Science Officer at Oncocyte. Dr. Schuetz developed the dd-cfDNA technology as CEO and CSO of Oncocyte subsidiary Chronix Biomedical alongside Dr. Julia Beck. The clinical presentation will be followed by an operational update and Q&A focused on the commercial launches of VitaGraft Kidney and GraftAssure by Josh Riggs. Investors may submit questions for the Q&A by emailing them to the contact information listed below. The date and time of the call will be announced in due course.
1 Mujtahedi, S.S., Yigitbilek, F., Ozdogan, E. et al. Antibody-Mediated Rejection: the Role of Plasma Cells and Memory B Cells. Curr Transpl Rep 8, 272–280 (2021). https://doi.org/10.1007/s40472-021-00342-1
About Oncocyte
Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:
VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/
GraftAssure™ - https://oncocyte.com/graftassure/
DetermaIO™ - https://oncocyte.com/determa-io/
DetermaCNI™ - https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
About Antibody-Mediated Rejection (AMR) in Kidney Transplant Recipients
Antibody-mediated rejection (AMR) is a major cause of kidney transplant failure, with late AMR affecting approximately 23,000 patients total in the U.S. There is no effective treatment for AMR and patient options are highly limited. Donor-specific antibody (DSA) production by plasma cells, and tissue infiltration of Natural Killer (NK) cells presumed to be involved in DSA-dependent microvascular inflammation, are both linked to AMR. Observations that both plasma cells and NK cells express high levels of CD38 have motivated the approach of targeting CD38 to deplete these cell populations to address AMR.
About Felzartamab
Felzartamab is an investigational therapeutic human monoclonal antibody directed against CD38, a protein expressed on mature plasma cells. Felzartamab has been shown in clinical studies to selectively deplete CD38+ plasma cells, which may allow applications that ultimately improve clinical outcomes in a broad range of diseases driven by pathogenic antibodies. Felzartamab is an investigational therapeutic candidate that has not yet been approved by any regulatory authority.
Forward-Looking Statements
Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the future of VitaGraft Kidney, the anticipation that Oncocyte and Bio-Rad's combined technology will be adopted around the world, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on Oncocyte or its subsidiaries’ financial and operational results, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte’s third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
FAQ
What are the key results of the Oncocyte VitaGraft Kidney study?
When were the results of the Oncocyte VitaGraft Kidney study published?
What is the significance of the VitaGraft Kidney test for kidney transplant patients?
What percentage of kidney transplant patients develop AMR?
How does the VitaGraft Kidney test work?
What are the potential new uses for the VitaGraft Kidney test?
What are the next steps for Oncocyte after the publication of the VitaGraft Kidney study results?
What is the investigational drug used in the VitaGraft Kidney study?
